Infectious Disease Management: Longhorn President Jeff Fischer at Nasdaq
IPO Edge hosted a fireside chat on July 29 at the Nasdaq MarketSite with Jeff Fischer, President of Longhorn Vaccines and Diagnostics. The in-person interview was joined by Editor-at-Large Jarrett Banks and they discussed the background in infectious diseases, what makes PrimeStore MTM different from other testing tools, the company’s vaccine and antibody portfolio and more.
Watch the full recording below:
About Jeff Fischer
Jeff Fischer, MBA, is the President of Longhorn and is responsible for oversight of all non-scientific aspects of the organization to include regulatory affairs.
Jeff co-founded the company and has served as its Chief Financial Officer from 2007-2017. From 1998-2005, Jeff served as an executive vice president and CFO in the biotechnology industry.
He is a former infantry officer in the United States Marine Corps and holds an MBA from the University of Texas at Austin.
About Longhorn Vaccines and Diagnostics
Longhorn is developing broad coverage vaccines and diagnostic tools for worldwide public health concerns such as anti-microbial resistance and sepsis, and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing broad coverage vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn products play a significant role to surveil, diagnose, prevent and treat the next infectious disease.
The company’s core product, PrimeStore® Molecular Transport Medium, is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases. Our expertise, through past and present team members, is creating novel technologies, generating broad intellectual property, conducting extensive studies and presenting them in peer reviewed publications and conferences, putting them up to regulatory scrutiny, and taking them through to commercialization.
As a small and focused team, we rely on outside experts in the fields of legal and regulatory affairs. We collaborate with government agencies and healthcare organizations to help surveil, diagnose, prevent and treat infectious diseases. Understanding the interconnection between people, animals, plants and their shared environments, we focus on infections in both humans and animals, such as Covid-19, African Swine Fever, RSV, avian influenza, influenza, Mycobacterium tuberculosis, Mpox, and other pathogens.
The company is based in Bethesda, MD, with a vaccine research and development facility in Gaithersburg, MD.
Contact:
Twitter: @IPOEdge
Instagram: @IPOEdge